Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Azd1722
2. Rdx5791
1. 1234423-95-0
2. Azd1722
3. Azd-1722
4. Tenapanor Free Base
5. Rdx-5791
6. Azd 1722
7. Rdx 5791
8. Ibsrela
9. Rdx5791
10. Wyd79216a6
11. 1234423-95-0 (free Base)
12. 3-((s)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-n-(26-((3-((s)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide
13. N,n'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis(((4s)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide)
14. Tenapanor [inn]
15. 1-[2-[2-[2-[[3-[(4s)-6,8-dichloro-2-methyl-3,4-dihydro-1h-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-[(4s)-6,8-dichloro-2-methyl-3,4-dihydro-1h-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea
16. Tenapanor [usan:inn]
17. Unii-wyd79216a6
18. Khk-7791
19. Tenapanor [mi]
20. Tenapanor (usan/inn)
21. Tenapanor [usan]
22. Tenapanor [who-dd]
23. Gtpl8449
24. Chembl3304485
25. Schembl15267600
26. Dtxsid40154016
27. Khk7791
28. Bdbm381823
29. Rdx013 Component Tenapanor
30. Bcp24892
31. Bcp28554
32. Ex-a2506
33. Rdx-013 Component Tenapanor
34. Mfcd28386333
35. Tenapanor; Azd1722; Rdx5791
36. Us10272079, Compound 002
37. Us10272079, Compound 180
38. Akos037648586
39. Tenapanor Component Of Rdx013
40. Cs-6273
41. Db11761
42. Tenapanor Component Of Rdx-013
43. Ac-36104
44. Bs-14732
45. Bt178667
46. Hy-15991
47. J3.655.031g
48. D11652
49. A929505
50. Q17122912
51. Azd 1722;azd1722;azd-1722;rdx5791;rdx 5791;rdx-5791
52. Azd-1722; Azd 1722; Azd1722; Rdx 5791; Rdx-5791; Rdx5791
53. 12,15-dioxa-2,7,9-triazaheptadecanamide, 17-(((3-((4s)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl)sulfonyl)amino)-n-(2-(2-(2-(((3-((4s)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl)sulfonyl)amino)ethoxy)ethoxy)ethyl)-8-oxo-
54. 17-[[[3-[(4s)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-n-[2-[2-[2-[[[3-[(4s)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide
Molecular Weight | 1145.0 g/mol |
---|---|
Molecular Formula | C50H66Cl4N8O10S2 |
XLogP3 | 5.1 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 29 |
Exact Mass | 1144.306793 g/mol |
Monoisotopic Mass | 1142.309743 g/mol |
Topological Polar Surface Area | 235 Ų |
Heavy Atom Count | 74 |
Formal Charge | 0 |
Complexity | 1770 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Tenapanor is indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in adults. It is also currently being investigated as a treatment for hyperphosphatemia in chronic kidney disease patients undergoing dialysis (NCT02081534 and NCT02675998).
Through the inhibition of dietary sodium absorption tenapanor causes an increase in water secretion into the intestines, thereby decreasing transit time and softening stool consistency.
A - Alimentary tract and metabolism
A06 - Drugs for constipation
A06A - Drugs for constipation
A06AX - Other drugs for constipation
A06AX08 - Tenapanor
Absorption
Tenapanor undergoes very minimal systemic absorption following oral administration. During clinical trials, plasma concentrations were below the limit of quantitation (i.e. less than 0.5 ng/mL) in the majority of samples from healthy subjects - for this reason, typical pharmacokinetic values related to absorption such as AUC and Cmax were unable to be ascertained. The effects of tenapanor are greatest when administered 5 to 10 minutes before meals.
Route of Elimination
Following administration of a radio labeled dose of tenapanor, 70% of the radioactivity was excreted in the feces within 120 hours of administration and 79% within 240 hours. Approximately 65% of the total dose is excreted as unchanged parent drug within 144 hours of administration. Only 9% of the administered dose was found in the urine, existing primarily as metabolites. Tenapanor's M1 metabolite is excreted unchanged in the urine and accounts for approximately 1.5% of the total dose within 144 hours of administration.
The majority of tenapanor's metabolism to its primary metabolite, M1, is catalyzed via CYP3A4/5. Exposure of tenapanor to hepatic CYP enzymes is likely limited due to its minimal systemic absorption, so its metabolism may be due to intestinal CYP enzyme activity. The M1 metabolite of tenapanor is a P-glycoprotein substrate and, in contrast to its parent drug, can be detected in plasma, reaching a Cmax of approximately 15 ng/mL at steady state. It is not considered active against NHE3.
Tenapanor's FDA label states that its half-life could not be determined during clinical trials due to its minimal systemic absorption resulting in plasma concentrations below the limit of quantitation (i.e. less than 0.5 ng/mL).
Tenapanor is a locally-acting small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), an antiporter expressed on the apical surface of enterocytes in the small intestine and colon which is involved in sodium-fluid homeostasis. By inhibiting this antiporter tenapanor causes retention of sodium within the lumen of the intestine - this results in an osmotic gradient that draws water into the lumen and softens stool consistency. There is some evidence that tenapanor can inhibit the uptake of dietary phosphorus in the gastrointestinal tract, though the exact mechanism of this activity has yet to be elucidated.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Global Sales Information
Market Place
ABOUT THIS PAGE
A Tenapanor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tenapanor, including repackagers and relabelers. The FDA regulates Tenapanor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tenapanor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tenapanor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tenapanor supplier is an individual or a company that provides Tenapanor active pharmaceutical ingredient (API) or Tenapanor finished formulations upon request. The Tenapanor suppliers may include Tenapanor API manufacturers, exporters, distributors and traders.
click here to find a list of Tenapanor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tenapanor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tenapanor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tenapanor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tenapanor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tenapanor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tenapanor suppliers with NDC on PharmaCompass.
Tenapanor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tenapanor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tenapanor GMP manufacturer or Tenapanor GMP API supplier for your needs.
A Tenapanor CoA (Certificate of Analysis) is a formal document that attests to Tenapanor's compliance with Tenapanor specifications and serves as a tool for batch-level quality control.
Tenapanor CoA mostly includes findings from lab analyses of a specific batch. For each Tenapanor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tenapanor may be tested according to a variety of international standards, such as European Pharmacopoeia (Tenapanor EP), Tenapanor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tenapanor USP).
LOOKING FOR A SUPPLIER?